scholarly journals INFLUENCE ON THE OUTCOME OF ART PROGRAMS OF FROZEN-THAWED BLASTOCYSTS EXPANDED ON FIVE OR SIX DAY

2021 ◽  
pp. 68-75
Author(s):  
A.O. Polumiskova ◽  
S.I. Tevkin ◽  
T.M. Jussubaliyeva ◽  
M.S. Shishimorova
Keyword(s):  
Pregnancy Rate ◽  
Assisted Reproductive Technologies ◽  
Reproductive Technologies ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Miscarriage Rate ◽  
Art Programs ◽  
Group A ◽  
The Difference ◽  
Group B

In order to increase the effectiveness of assisted reproductive technologies (ART) programs, it is essential to improve and develop conditions of embryo culture prior its transfer or cryopreservation of expanded blastocysts on the day 5 or 6. The aim of the study was to assess the effect of human blastocysts’ expansion timing on clinical pregnancy rate (CPR), miscarriage rate (MR) and take-home baby rate (THBR) in frozen-thawed cycles during ART programs. The study involved 2275 frozen embryo transfers (FET) of blastocysts expanded on the day 5 (group A) and 170 FET of blastocysts expanded on the day 6 (group B). The pregnancy rates in both groups were 50.8% and 46.5% respectively. There were no statistically significant differences in clinical pregnancy rate 37.4% and 37.0%, miscarriage rate 26.0% and 21.5% in both groups, respectively. THBR, as the main indicator of efficiency in the programs with transfer of post thawed expanded blastocysts on the day 5 (group A) or 6 (group B) were 36.5% and 35.2%, respectively (the difference is insignificant). In conclusion, in cryoprotocols the day of blastocyst expansion (day 5 or 6 of development) does not statistically affect PR, MR and THBR. In FET programs the quality of blastocyst (excellent and good) should be prioritized regardless of the day of cryopreservation.

scholarly journals Myoinositol with Metformin and Myoinositol alone in infertile PCOS women undergoing ovulation induction cycles: A comparative study

2021 ◽  
pp. 1-10
Author(s):  
Pramod Gade ◽  
Aher Gautam S ◽  
Vazifdar Sharmeen
Keyword(s):  
Pregnancy Rate ◽  
Prospective Observational Study ◽  
Outcome Measure ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Single Drug ◽  
Group A ◽  
The Difference ◽  
Group B ◽  
Hormonal Levels

Background: This was a prospective observational study conducted over a twelve-month duration in our institute to compare the combined effect of metformin and myoinositol with metformin alone. Method: A total of sixty patients were included in the study, and they were divided into two groups depending on whether they were given the combination or the single drug. Group A (n=30) was given Myoinositol 600 mg+Metformin 500 mg thrice a day, and Group B ( n=30) was given only Myoinositol 600 mg thrice a day. The outcome measure was clinical pregnancy rate and improvement in clinical and hormonal parameters after drug therapy. Results: BMI (p<0.01), modified Ferriman Gallaway score (p>0.05), and the was a significant improvement in the hormonal parameters (LH,FSH) in both the groups and the levels were found to be comparable after a period of 6 months. The clinical pregnancy rate after six cycles of ovulation was significantly higher in Group A as compared to Group B. In Group A, the total clinical pregnancy rate was 43.33%, and in Group B, it was 26.67%, respectively, and the end of 6 months and the difference was statistically significant (p = <0.01) Conclusion: Equal response in reduction of hormonal levels and clinical and laboratory parameters were seen in both groups, while better results in terms of clinical fertility rates were observed in the group that was given a combination of myoinositol with metformin.

P–347 A comparative RCT of Intrauterine-GCSF versus Subcutaneous-GCSF in Thin Endometrium in IVF-ICSI Cycles

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
P C Jindal ◽  
M Singh
Keyword(s):  
Pregnancy Rate ◽  
Embryo Transfer ◽  
Endometrial Thickness ◽  
Serum Levels ◽  
Abortion Rate ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Thin Endometrium ◽  
Group A ◽  
Group B

Abstract Study question Does GCSF by intrauterine route leads to better result in the treatment of thin endometrium as compared to GCSF by the subcutaneous route, in IVF-ICSI Cycles? Summary answer Yes, GCSF by intrauterine route leads to better result in the treatment of thin endometrium as compared to subcutaneous-GCSF, in ART Cycles? What is known already GCSF, is a member of the colony stimulating factor family of cytokines and growth factors. GCSF receptors are expressed in high concentration on dominant follicle, particularly at preovulatory stage.The endometrium also shows an increased expression of these receptors. GCSF concentration rises in the follicular fluid at the same time. Serum levels of GCSF are found to be in direct correlation with levels of GCSF in follicular fluid. Serum levels increase progressively from the day the embryo-transfer to the day of implantation. GCSF has been found to be beneficial in patients with thin endometrium and recurrent implantation failure. Study design, size, duration This was a RCT conducted between 2018–2019. 30 patients with thin endometrium were enrolled in each group. In either group, GCSF was given if endometrium was less than 7mm on day 14, maximum of two doses were administered. Patients undergoing frozen embryo transfer were recruited in the study, after meeting the inclusion and exclusion criteria. Primary outcome measured was increase in endometrium thickness and the secondary outcome was the clinical pregnancy rate and abortion-rate. Participants/materials, setting, methods 60 patients with thin endometrium were randomly divided into two groups. Group A: Inj. GCSF (300 mcg/1 ml) subcutaneously on Day 14 onwards alternate days for two doses. Group B: Inj. GCSF (300 mcg/1 ml) instilled slowly into the uterine cavity using an intrauterine insemination (IUI) catheter under USG guidance. Endometrial thickness was assessed after 48 h. If endometrial thickness was found to be &lt; 7 mm, a second infusion of GCSF was carried out. Main results and the role of chance In the subcutaneous group (group-A) the mean endometrial thickness before GCSF injection was 5.8 ± 0.6 mm and, after injection it increased to 6.9 ± 0.4 mm. Similarly, in the intrauterine group (group-B) the mean endometrial thickness before GCSF was 5.9 ± 0.7 which increased to a mean of 7.9 ± 0.5 after GCSF instillation. The difference between endometrial thickness before and after intrauterine infusion of GCSF was more than that in the subcutaneous group. In group-A, 08 patients conceived out of 30 patients ( clinical pregnancy rate 26.6%) and in group B 11 conceived out of 30 patients in whom GCSF was instilled intrauterine (pregnancy rate 36.6%). Thus, there was a difference in the clinical pregnancy rate in the two groups, the intrauterine group yielding a higher clinical pregnancy rate, but it was not statistically significant. Because of the thin endometrium, we found an abortion rate of 25% (2/8) in the subcutaneous-GCSF group, and an abortion rate of 18% (2/11) in the intrauterine GCSF group. Limitations, reasons for caution There are few potential limitations because of the small sample size. Confounders such as obesity, smoking and alcohol intake, presence of adenomyosis and endometriosis, were not taken into consideration. Though prevalence of obesity is usually low in Indian women. Habits of smoking and alcohol are exceedingly uncommon in Indian women. Wider implications of the findings: Use of GCSF plays an important role in management of patients of thin endometrium undergoing embryo transfer. It is an easily available and economical preparation in developing countries and the intrauterine instillation of GCSF can be easily practiced in an ART unit with good results in resistant thin endometrium patients. Trial registration number Not applicable

P–254 The outcome of artificial reproductive technologies (ART) cycles with transfer of frozen-thawed blastocysts depending on whether expanded on day 5 or day 6

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
A Polumiskova ◽  
S Tevkin ◽  
M Shishimorova ◽  
T Jussubaliyeva
Keyword(s):  
Pregnancy Rate ◽  
Positive Outcome ◽  
Reproductive Technologies ◽  
Endometrial Receptivity ◽  
Ongoing Pregnancy ◽  
Miscarriage Rate ◽  
Ongoing Pregnancy Rate ◽  
Preimplantation Genetic Testing ◽  
Group A ◽  
Group B

Abstract Study question Is there a difference in ART cycle results after frozen embryo transfer (FET), depending on whether blastocysts were cryopreserved on day 5 or 6? Summary answer There’s no statistical difference in the clinical pregnancy rate (CPR), life birth rate (LBR), miscarriage rate (MR) between embryos frozen on day 5 and 6. What is known already Currently, opinions differ regarding this topic. Previous studies demonstrated no difference in ongoing pregnancy rates between embryos frozen on day 5 (group A) or day 6 (group B) after FET. However, metanalysis (2019) suggested higher CPR and LBR after transferring embryos from group A rather than group B. It has also been established that ovarian stimulation leads to endometrial changes that result in deleterious effects on the implantation window and endometrial receptivity. Consequently, fresh transfers were excluded. Due to hormonal priming of endometrial receptivity, the same pregnancy outcomes should be expected with frozen-thawed blastocysts (day 5 vs 6). Study design, size, duration Retrospective cohort study was conducted between January 2015 and December 2018 with selected group of patients under 40 years of age. Group A consisted of 2275 cryotransfers of blastocyst expanded on day 5; group B included 170 cryotransfers of blastocyst on day 6. Both groups had an average of 1,52 embryos transferred per patient. Participants/materials, setting, methods Embryos were vitrified and warmed with Cryotop method (Kitazato, BioPharma). Blastocysts were scored according to Gardner and Schoolcraft grading system. Only expanded on day or 6 blastocysts of excellent and good (AA, AB, BA, BB) quality were selected. The embryos were cultured in CSC medium (Irvine Scientific) for 2–4 hours prior intrauterine transfer. The cycles with donor gametes, surrogacy and preimplantation genetic testing (PGT) were excluded. Statistical validity was assessed by Pearson’s chi-squared test. Main results and the role of chance The rates of the CPR, the ongoing pregnancy rate (OPR) and the LBR between group A and B were 50,8% (1157/2275) vs 46,5% (79/170) (p = 0,26), 37,4% (852/2275) vs 37,0% (63/170) (p = 0,91), 36,5% (832/2275) vs 35,2% (60/170) (p = 0,73) respectively and no significant differences were found in each category. Moreover, similarly there were no significant differences in the miscarriage rate 26,0% (301/1157) and 21,5% (17/79) (p = 0,37) as well Limitations, reasons for caution The study is limited due to uneven distribution of patients in both groups and by a low number of participants. The grading of blastocysts’ quality is also subjected to a human factor. Wider implications of the findings: This study confirms that frozen-thawed blastocysts do not seem to exhibit a difference in the CPR, OPR, LBR and MR whether they were expanded on day 5 or day 6. The cryopreservation of day 6 blastocyst can increase the chances of the patient for the positive outcome. Trial registration number Not applicable

scholarly journals DYSMORPHISMS OF OOCYTES IN ART PROCEDURES: A LITERATURE REVIEW

2021 ◽  
pp. 44-53
Author(s):  
G.M. Karibayeva ◽  
S.I. Tevkin ◽  
T.M. Jussubaliyeva ◽  
M.S. Shishimorova
Keyword(s):  
Literature Review ◽  
Pregnancy Rate ◽  
Assisted Reproductive Technologies ◽  
Morphological Changes ◽  
Reproductive Technologies ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Human Oocytes

Relevance: Assisted reproductive technologies (ART) are rapidly developing and in recent decades have become increasingly important due to the growing number of infertile couples around the world. Human oocytes are the main objects used in ART procedures. Consequently, the quality of oocytes can determine the key parameters of ART. The purpose of this review was to analyze the literature and the results of studies in the field of ART devoted to extracytoplasmic dysmorphisms of human oocytes – morphological changes outside the cytoplasmic structure of oocytes, their effect on fertilization, cleavage, implantation frequency, clinical pregnancy rate, as well as the possibility of their use as biomarkers for predicting the quality of embryos, blastocysts, and their further implantation potential. Materials and Methods: This literature review was based on a search conducted among domestic and foreign publications for 2000-2020 available in Russian and international search systems (PubMed, eLibrary) using the keywords «infertility,” “IVF,” «oocyte,” “morphological assessment of oocytes,” “dysmorphisms of oocytes ,” and “ assisted reproductive technologies.” Results: This literature review contains literature data and the analysis of research results in the field of ART devoted to the morphological qualities and abnormalities (dysmorphisms) of human oocytes. It describes the types of extracytoplasmic abnormalities encountered in the clinical practice of in-vitro fertilization, their effect on fertilization, cleavage, implantation rate, and clinical pregnancy rate, as well as the possibility of their use as biomarkers to predict the quality of embryos and blastocysts and their further implantation potential.

P–375 Intralipid supplementation in women with unexplained recurrent implantation failure and elevated uterine natural killer cell levels - A randomized placebo controlled trial

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Y Dogra ◽  
N Singh ◽  
S Mathur
Keyword(s):  
Pregnancy Rate ◽  
Controlled Trial ◽  
Killer Cell ◽  
Live Birth Rate ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Unk Cells ◽  
Group A ◽  
Group B ◽  
Unk Cell

Abstract Study question Does intralipid supplementation in women with unexplained recurrent implantation failure (RIF) with elevated uterine natural killer cell (uNK) levels improve pregnancy outcomes during IVF? Summary answer Intralipid supplementation appears to improve clinical pregnancy rate in women with unexplained RIF with elevated uNK cell levels. What is known already The increased numbers of uNK cells in peri-implantation endometrium have been reported in women with recurrent miscarriage (RM) and RIF after IVF. However, reports are contradictory when it comes to correlation of increased numbers of uNK cells with pregnancy outcome. Current opinion suggests there is a potential for intralipid therapy in improving reproductive outcome, although data on live birth rate is very limited. No studies have assessed the effect of intralipid on IVF outcomes in RIF women based on elevated uNK cells. Identified studies have all used pNK cell testing as preferred diagnostic tool for analysis of NK cell levels. Study design, size, duration A randomized placebo controlled trial was conducted at Division of Reproductive Medicine at tertiary care institute. Thirty women with RIF and fifty fertile controls with age &lt;35 years having regular menstrual cycles and no hormonal treatment in last 3 months were enrolled in the study from January 2019 to December 2020 for uNK cell testing. Randomization was done using random numbers and sealed envelopes. Only the subjects were masked and allocation concealment was done. Participants/materials, setting, methods Subjects included RIF 20–35 years, normal ovarian reserve, unexplained and tubal factors, normal karyotype and normal uterine cavity. Cut off for uNK cells was derived from fertile controls by immunohistochemical staining of CD56+ cells from midluteal endometrial biopsy sample. Subjects with elevated uNK cell levels were randomized during IVF to group A (Intralipid) or group B ( saline ). The infusion was repeated within one week of positive pregnancy test and then every 2 weeks. Main results and the role of chance The mean age and BMI were comparable between fertile control and study group(29.45±3.3 vs 31.17±3.3 years, 22.97±1.89 vs 23.21±2.2 kg/m2 ;p&gt;0.05). The median uNK cell levels was 7%(used as cut off) in fertile controls and 13.5% in RIF. 18 women (60%, 18/30) with RIF who had elevated uNK cell level (&gt;7%) were randomized. Four women were lost to follow up. The median age, BMI, number of previous failed cycles and duration of infertility were comparable between Group A(n = 7) and Group B(n = 7){30(IQR:27–31) vs 33(IQR:30–34)years, 22.7(IQR:21.08–24.4) vs 22.6(IQR:21.37–24.2)kg/m2, 2(IQR:2–3) vs 2(IQR:2–3), 8(IQR:7–8) vs 8(IQR:7–10)years}. The median FSH, AMH and AFC were 5.86(IQR:5.13–7.67)mIU/l, 2.4(IQR:2.16–6.12)ng/ml, 10(IQR:8–12) in Group A which were comparable with Group B {6.2(IQR:4.78–6.5)mIU/l, 4.8(IQR:2.67–6.25)ng/ml, 12(IQR:12–16) }. All patients underwent antagonist protocol. The clinical pregnancy rate was 57.14%(4/7) in group A which was significantly higher as compared to 28.6%(2/7) in group B(p &lt; 0.05). None of the patients reported any side effects due to intralipid. Limitations, reasons for caution The limitation of present study is its small sample size. However, the study is currently recruiting more RIF patients, and these are the interim results of the same. More RCTs with larger sample size are required to assess the efficacy of intralipid in this specific subset of population. Wider implications of the findings: The present study suggests the beneficial effect of intralipid in women with unexplained RIF with elevated uNK cell levels in increasing the chemical and clinical pregnancy rate. However, ongoing pregnancy rate and live birth rate should be investigated further in this subset of population. Trial registration number CTRI/2019/01/017213

scholarly journals Comparative Analysis of Effectiveness of Clomiphene Citrate and Letrozole Combined with Low Dose Human Menopausal Gonadotropin for Controlled Ovarian Stimulation in Intrauterine Insemination Cycles

2021 ◽  
Vol 73 (3) ◽  
pp. 198-203
Author(s):  
Padmalaya Thakur ◽  
Sujata Pradhan
Keyword(s):  
Pregnancy Rate ◽  
Ovarian Stimulation ◽  
Low Dose ◽  
Intrauterine Insemination ◽  
Clomiphene Citrate ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Controlled Ovarian Stimulation ◽  
Human Menopausal Gonadotropin ◽  
Group B

Objective: To compare the efficacy of clomiphene citrate and letrozole in combination with low dose human menopausal gonadotropin for controlled ovarian stimulation in intrauterine insemination (IUI) cycles.Methods: During January-2018 to December-2019 for intending 496 IUI cycles, controlled ovarian stimulation was performed with either clomiphene or letrozole combined with human menopausal gonadotropin (hMG), in two arms:  subjects in one arm (Group A) were with clomiphene and hMG in 222 cycles; those in the second arm (Group B) were with letrozole and hMG in 274 cycles. Pregnancy rate and clinical pregnancy rate of both groups were considered as the primary outcomes.Results: Patient characteristics like female age, indications for IUI, type of IUI, endometrial thickness and total motile fraction (TMF) of spermatozoa of male partners were seen similar in both groups. The letrozole-hMG group (Group B) had significantly higher numbers of cycles with single dominant follicle (P=0.01) and human chorionic gonadotropin (hCG) was more frequently used as the ovulation trigger (P=0.03). Pregnancy rate (18.5% vs. 15.3%, P=0.35) and clinical pregnancy rate (18.5% vs. 15.3%, P=0.35) were similar in groups A and B, respectively.Conclusion: Clomiphene citrate and letrozole combined with low dose human menopausal gonadotropin were equally effective for controlled ovarian stimulation in IUI cycles.

scholarly journals Comparison of Pregnancy and Neonatal Outcomes of Single Frozen Blastocyst Transfer Between Letrozole-induction and HRT Cycles in Patients With Abnormal Ovulation

2021 ◽  
Author(s):  
Junwei Zhang ◽  
Zhen Li ◽  
Lijun Sun ◽  
Yichun Guan ◽  
Mingze Du
Keyword(s):  
Pregnancy Rate ◽  
Gestational Age ◽  
Low Birthweight ◽  
Statistical Significance ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Neonatal Outcomes ◽  
Large For Gestational Age ◽  
Secondary Outcome ◽  
Miscarriage Rate

Abstract Background: The use of frozen embryo transfer (FET) cycles has dramatically risen. The optimal endometrial preparation method for women undergoing FET is of utmost importance to provide the optimal chances of pregnancy. For patients with abnormal ovulation in particular, there have been few studies on FET protocols; notably, most of these studies focus only on the clinical pregnancy rate or live birth rate (LBR) and pay little attention to the regimen’s safety for offspring.Methods: It was a retrospective cohort study. First FET cycle with a single blastocyst from whole embryo frozen IVF/ICSI at the Reproductive Center of Third Affiliated Hospital of Zhengzhou University between January 2016 and January 2020. The LBR was the primary outcome of interest. The secondary outcome measures were miscarriage rate and offspring safety, including preterm birth, low birthweight (LBW), small-for-gestational age (SGA), macrosomia and large-for-gestational age (LGA).Results: In total, 2782 FET cycles met the eligibility criteria for analysis. Additionally, there were 1178 singleton births from FET cycles. The clinical pregnancy rate was 58.4% in the L-FET group and 54.5% in the HRT group, with no statistical significance (P=.116). The miscarriage rate was higher in the HRT group than in the L-FET group (21.7% vs. 14.3%, P=.005). The LBR was significantly higher in the L-FET group than in the HRT group (49.6% vs. 41.7%, P=.001). Neonatal outcomes were similar between the two groups. After adjustments for confounding factors, the LBR was higher in the L-FET group (aOR 1.30, 95% CI 1.06-1.58). The rate of miscarriage was lower in the L-FET group (aOR 0.63, 95% CI 0.44-0.90). Conclusion: For patients with abnormal ovulation, the L-FET regimen has a higher LBR and lower miscarriage rate than HRT. The neonatal outcomes were similar between the two groups.

Optimization of prevalual preparation of endometry before the treatment аrt methods in patients with tubal-periotional infertility by application of the injection-screetching procedure

2018 ◽  
pp. 87-91
Author(s):  
L.V. Suslikova ◽  
◽  
A.V. Serbenuyk ◽  
Keyword(s):  
Assisted Reproductive Technologies ◽  
Basal Layer ◽  
Reproductive Technologies ◽  
Follicular Phase ◽  
Optimal Time ◽  
Repeated Cycle ◽  
Endometrial Scratching ◽  
Group A ◽  
Group B ◽  
Control Stimulation

The article presents an analysis of literature data and the results of own prospective studies of the application of the local iatrogenic injury method with the parallel introduction of plasma enriched with platelets into the basal layer of the endometrium in pregravid preparation for treatment with assisted reproductive technologies (ART) in patients with tubal peritoneal infertility and marked lag development of the endometrium. The objective: was to determine the optimal time for the injection of scratch scratching in pregravid preparation before the next cycle of ART treatment in patients with tubal peritoneal infertility and marked lag in the development of the endometrium. Materials and methods. The study included 109 patients with unsuccessful attempts to treat ART with a tubal peritoneal factor of infertility with a marked degree of lag in the development of the endometrium according to absolute indications. The subjects were divided into three groups. Group A – 47 patients who experienced a marked lag in the development of the endometrium during the control stimulation of superovulation during ART (ETC + ET) and suggested the application of the procedure of injection scaling of the endometrium on the 7th day of the stimulation cycle (CA). Group B – 32 patients who underwent the procedure of injection endometrial scratching on the 22nd day of the menstrual cycle (MC), which preceded the repeated cycle of CGI + ET. Group B – 30 patients who underwent the procedure of injection endometrial scratching on the 8th day of the MC, which preceded the repeated cycle of CCN + ET. Results. The use of injection scratches is more effective in improving the clinical outcomes of ART by using the methods of ART (CAS + ET) in the case of a pronounced delay in the development of the endometrium in the follicular phase of the CA on the 6th to 7th day of gonadotropin use. During treatment with ART, the frequency of pregnancy for each transfer of embryos (CHNBPE) was significantly lower, amounting to 9.4% (3 of 32) in group B and 7.1% (2 of 28) in group B than CHNBPE in group A – 27.7% (13 of 47). The frequency of early reproductive losses in group A was 23.1% (3 of 13), in group B – 66.7% (2 of 3), in group B – 50% (1 of 2). Conclusion. During the study of the optimal period for the appointment of injection scratching, it was found that injection endometrial scratching using autoplasma enriched with platelets demonstrates the best pregnancy rate for each transfer of embryos and low early reproductive loss if performed in the follicular phase of the stimulation cycle by 6–7th day of gonadotropins). Key words: infertility, methods of assisted reproductive technology, hypoplasia of the endometrium, hysteroscopy, plasma-riched platelets.

P–318 Short (seven days) versus conventional (fourteen days) estrogen priming in an artificial frozen embryo transfer cycle: a randomised controlled trial

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
A Racca ◽  
S Santos-Ribeiro ◽  
D Panagiotis ◽  
L Boudry ◽  
S Mackens ◽  
...  
Keyword(s):  
Pregnancy Rate ◽  
Embryo Transfer ◽  
Live Birth ◽  
Transvaginal Ultrasound ◽  
Clinical Pregnancy ◽  
Frozen Embryo Transfer ◽  
Significant Difference ◽  
Group A ◽  
Group B ◽  
The Impact

Abstract Study question What is the impact of seven days versus fourteen days’ estrogen (E2) priming on the clinical outcome of frozen-embryo-transfer in artificially prepared endometrium (FET-HRT) cycles? Summary answer No significant difference in clinical/ongoing pregnancy rate was observed when comparing 7 versus 14 days of estrogen priming before starting progesterone (P) supplementation. What is known already One (effective) method for endometrial preparation prior to frozen embryo transfer is hormone replacement therapy (HRT), a sequential regimen with E2 and P, which aims to mimic the endocrine exposure of the endometrium in a physiological cycle. The average duration of E2 supplementation is generally 12–14 days, however, this protocol has been arbitrarily chosen whereas, the optimal duration of E2 implementation remains unknown. Study design, size, duration This is a single-center, randomized, controlled, open-label pilot study. All FET-HRT cycles were performed in a tertiary centre between October 2018 and December 2020. Overall, 150 patients were randomized of whom 132 were included in the analysis after screening failure and drop-out. Participants/materials, setting, methods The included patients were randomized into one of 2 groups; group A (7 days of E2 prior to P supplementation) and group B (14 days of E2 prior to P supplementation). Both groups received blastocyst stage embryos for transfer on the 6th day of vaginal P administration. Pregnancy was assessed by an hCG blood test 12 days after FET and clinical pregnancy was confirmed by transvaginal ultrasound at 7 weeks of gestation. Main results and the role of chance Following the exclusion of drop-outs and screening failures, 132 patients were finally included both in group A (69 patients) or group B (63 patients). Demographic characteristics for both groups were comparable. The positive pregnancy rate was 46.4% and 53.9%, (p 0.462) for group A and group B, respectively. With regard to the clinical pregnancy rate at 7 weeks, no statistically significant difference was observed (36.2% vs 36.5% for group A and group B, respectively, p = 0.499). The secondary outcomes of the study (biochemical pregnancy, miscarriage and live birth rate) were also comparable between the two arms for both PP and ITT analysis. Multivariable logistic regression showed that the HRT scheme is not associated with pregnancy rate, however, the P value on the day of ET is significantly associated with the pregnancy outcome. Limitations, reasons for caution This study was designed as a proof of principle trial with a limited study population and therefore underpowered to determine the superiority of one intervention over another. Instead, the purpose of the present study was to explore trends in outcome differences and to allow us to safely design larger RCTs. Wider implications of the findings: The results of this study give the confidence to perform larger-scale RCTs to confirm whether a FET-HRT can be performed safely in a shorter time frame, thus, reducing the TTP, while maintaining comparable pregnancy and live birth rates. Trial registration number NCT03930706

P–231 Transnational oocyte donation program between Italy and Spain based on transport of vitrified oocytes: a five-years experience

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
A Volpes ◽  
S Gullo ◽  
M Modica ◽  
P Scaglione ◽  
A Marino ◽  
...  
Keyword(s):  
Pregnancy Rate ◽  
Ovarian Function ◽  
Multiple Pregnancy ◽  
Oocyte Donation ◽  
Blastocyst Stage ◽  
Clinical Pregnancy ◽  
Clinical Pregnancy Rate ◽  
Egg Donation ◽  
Cleavage Stage ◽  
Miscarriage Rate

Abstract Study question What is the clinical efficacy of an oocyte donation program based on the transportation of vitrified oocytes between two countries? Summary answer The transnational oocyte donation program is efficient, safe and comparable to other strategies (transport of frozen sperm and embryos). What is known already Egg donation represents a valid treatment strategy for women who have exhausted their ovarian function and it has considerably increased in the last years. In Italy, egg donation is allowed after the judgment of the Constitutional Court n. 162 in 2014 but no reimbursement for the donors is provided. For this reason, the number of voluntary donors is irrelevant. Therefore, the great majority of egg donation cycles is carried out by using imported cryopreserved oocytes from foreign countries. However, recent evidence has questioned the overall efficacy of this strategy in comparison with the shipment of frozen sperm and vitrified embryos. Study design, size, duration A retrospective cohort study was conducted between July 2015-December 2020 at two private IVF clinics. 264 couples were treated (mean maternal age: 43.1± 4.6 years, range: 26–51; mean donor age: 24 ±3 years, range: 20–33) with vitrified oocytes shipped from a single Spanish egg bank (IMER, Valencia) to the receiving reproductive clinic in Italy (ANDROS Clinic, Palermo). All the oocytes for each batch were thawed. Participants/materials, setting, methods The primary outcome of this study was the cumulative clinical pregnancy rate (CPR) among the completed cycles for each batch of oocytes. Those cycles in which a clinical pregnancy was obtained, or all embryos derived by a single batch of oocytes had been transferred or no embryo was produced were defined as completed. In addition to main analyses, sensitivity analysis was performed to examine how the number of inseminated oocytes may affect CPR. Main results and the role of chance 2,367 oocytes in 355 batches were sent from Spain to Italy. 2,209 oocytes in 334 batches for 264 patients were thawed with a survival rate of 82.4% (1,821/2,209). The mean number of oocytes received per patient was 6.6 ± 1.0. The fertilization rate was 72.1% (1,312/1,821). 499 embryos were transferred (38.0%), 335 at the cleavage stage (67.1%) and 164 at the blastocyst stage (32.9%); 197 supernumerary embryos were vitrified (15.0%), 18 at the cleavage stage (9.1%) and 179 at the blastocyst stage (90.9%). 616 embryos were not viable (47.0%). No more than two embryos were transferred for each embryo transfer (ET). The completed cycles were 307 out of 334 (91.9%). The CPR per completed cycles was 46.6% (143/307) and 54.2% per patient (143/264). Clinical pregnancy rate per fresh ET in completed cycles with supernumerary cryopreserved embryos was significantly higher compared with that of the completed cycles without surplus embryos (56/101 versus 68/193, p = 0.001). Logistic regression revealed that the number of inseminated oocytes was positively associated with CPR in a significant manner (B = 0.220, p = 0.007; OR = 1.25, 95%CI=1.06–1.47). The multiple pregnancy rate was 15.4% (1 triplet and 21 twin pregnancies). The miscarriage rate was 22.4% (32/143). Limitations, reasons for caution The retrospective design of the study needs to be confirmed in larger and multicenter prospective studies comparing the strategy of vitrified donated oocytes and fresh ET with the policy of fresh donated oocyte and frozen/thawed ET. Wider implications of the findings: The transnational oocyte donation program with vitrified oocytes is associated with good success rates. The number of inseminated oocytes represents a crucial factor for increasing the CPR, improving the embryo selection for fresh ET and giving more chances of pregnancy with the transfer of surplus vitrified embryos. Trial registration number Not applicable

Sign in / Sign up

Export Citation Format

Share Document